
**ISSN Print:** 2664-8865
**ISSN Online:** 2664-8873
**Impact Factor:** RJIF 5.48
IJIR 2024; 6(1): 35-39
www.immunologyjournal.in
Received: 06-12-2024
Accepted: 11-01-2024

**Dr. Antonio Vitale**
Department of Microbiology, University of Milan, Milan, Italy

**Dr. Kevin Marchetti**
Department of Microbiology, University of Milan, Milan, Italy

**Corresponding Author:**
**Dr. Antonio Vitale**
Department of Microbiology, University of Milan, Milan, Italy

# Exploring the synergistic effects of bacterial lysates and antibiotics in infectious disease therapy

**Dr. Antonio Vitale and Dr. Kevin Marchetti**

**DOI:** https://doi.org/10.33545/26648865.2024.v6.i1a.33

**Abstract**
This case series explores the synergistic effects of bacterial lysate immunotherapy in conjunction with antibiotic treatment in managing various infectious diseases. The study examines the clinical outcomes, immune response modulation, and antibiotic resistance patterns in patients treated with this combination therapy. We present a detailed analysis of five cases involving different infectious diseases, focusing on the rationale for treatment selection, therapeutic protocols, patient response, and overall efficacy.

**Keywords:** Bacterial lysates, antibiotics, infectious diseases, immunotherapy, antibiotic resistance, case series, synergistic effects

## Introduction
The global rise of antibiotic-resistant pathogens poses a significant challenge to public health, complicating the treatment of infectious diseases and leading to increased morbidity, mortality, and healthcare costs. The overuse and misuse of antibiotics have accelerated the development of resistant strains, diminishing the efficacy of standard antimicrobial therapies and necessitating the urgent need for alternative or adjunctive therapeutic strategies. This growing threat has prompted researchers and clinicians to explore innovative approaches that can enhance treatment outcomes while mitigating the spread of resistance.

One promising approach that has garnered increasing attention is the use of bacterial lysates. Bacterial lysates are biological preparations derived from inactivated or lysed bacterial cells, containing various bacterial components such as cell wall fragments, DNA, and other intracellular materials. Unlike traditional vaccines, which are designed to protect against specific pathogens, bacterial lysates are intended to modulate the immune system in a broader, non-specific manner. By stimulating both innate and adaptive immune responses, bacterial lysates can enhance the body's natural defenses against a wide range of pathogens, potentially reducing the frequency and severity of infections.

The immunomodulatory properties of bacterial lysates make them particularly attractive in the context of recurrent and chronic infections, where the immune system may be weakened or dysregulated. Bacterial lysates have been shown to boost the production of key immune factors, such as secretory IgA (sIgA) and various cytokines, which play critical roles in mucosal immunity and systemic immune responses. These effects not only help in preventing the recurrence of infections but also in shortening the duration and severity of active infections.

## Objective
The objective of this study is to evaluate the synergistic effects of bacterial lysate immunotherapy combined with antibiotics in reducing infection recurrence, enhancing immune response, and minimizing antibiotic usage in the treatment of recurrent and chronic infectious diseases.

## Synergistic Effects of Bacterial Lysates and Antibiotics
The integration of bacterial lysate immunotherapy with antibiotic treatment offers significant advantages in managing infectious diseases, particularly in reducing infection recurrence,

enhancing antibiotic efficacy, and potentially decreasing the overall use of antibiotics. The synergistic effects observed in clinical studies highlight the promise of this combination therapy in improving patient outcomes, especially in cases of recurrent infections and antibiotic resistance.

**Reduction in Infection Recurrence**

One of the most significant benefits of combining bacterial lysates with antibiotics is the notable reduction in the frequency and severity of infection recurrences. Bacterial lysates function by enhancing immune surveillance and memory, leading to a more robust and sustained immune response against pathogens. This is particularly important in patients with recurrent infections, where the immune system may be unable to mount an effective response on its own.

For instance, a study by Esposito *et al*. (2018) [1] involving patients with recurrent respiratory tract infections (RTIs) demonstrated that those receiving a combination of bacterial lysates and antibiotics experienced a marked decrease in infection episodes compared to those treated with antibiotics alone. Specifically, the group receiving bacterial lysates saw a reduction in RTI episodes by approximately 40% over a six-month period, compared to a 20% reduction in the antibiotic-only group. This significant difference underscores the role of bacterial lysates in reducing the burden of recurrent infections by priming the immune system for a more effective response upon subsequent pathogen exposure.

Furthermore, bacterial lysates have been shown to enhance the production of secretory IgA (sIgA), a key component of mucosal immunity. In a randomized controlled trial by Cazzola *et al*. (2015) [2], patients treated with bacterial lysates demonstrated a 30% increase in sIgA levels compared to baseline, correlating with a reduced incidence of recurrent infections. This increase in sIgA levels enhances the immune system’s ability to neutralize pathogens at mucosal surfaces, thereby preventing the establishment of new infections.

**Enhanced Antibiotic Efficacy**

The efficacy of antibiotics can be significantly enhanced when combined with bacterial lysate immunotherapy. Bacterial lysates stimulate the immune system, leading to a more effective clearance of infections, which in turn reduces the bacterial load and the duration of antibiotic therapy required. This synergistic effect is particularly beneficial in cases of chronic infections or those caused by antibiotic-resistant pathogens, where the immune system alone may struggle to eliminate the infection.

For example, in a study involving patients with chronic sinusitis, Cingi *et al*. (2011) [3] found that those treated with a combination of bacterial lysates and antibiotics showed a 50% faster resolution of symptoms compared to those treated with antibiotics alone. The study reported that the average duration of antibiotic therapy was reduced by two weeks in the combination therapy group, highlighting the potential of bacterial lysates to enhance the effectiveness of antibiotics. Additionally, the bacterial load, as measured by quantitative cultures, was significantly lower in the combination therapy group, suggesting that the immune-boosting effects of bacterial lysates contributed to a more rapid and complete eradication of the infection.

The role of bacterial lysates in enhancing antibiotic efficacy is further supported by their ability to modulate the host immune response. By activating innate immune cells such as macrophages and dendritic cells, bacterial lysates promote a more aggressive immune attack on pathogens, thereby complementing the action of antibiotics. An *in vitro* study by de Benedetti *et al*. (2017) [4] demonstrated that bacterial lysates could increase the phagocytic activity of macrophages by up to 60%, leading to more efficient pathogen clearance. This enhanced phagocytic activity is crucial in the context of infections caused by antibiotic-resistant organisms, where the immune system's ability to eliminate the pathogen can be the deciding factor in the outcome of the infection.

**Potential Reduction in Antibiotic Use**

The immunomodulatory effects of bacterial lysates not only enhance the efficacy of antibiotics but also have the potential to reduce the overall need for antibiotic therapy. By preventing infection recurrences and enhancing the immune response, bacterial lysates can decrease the frequency and duration of antibiotic courses, thereby mitigating the risk of developing antibiotic resistance.

A study on patients with recurrent urinary tract infections (UTIs) by Naber *et al*. (2019) [5] illustrated this potential. The study found that patients treated with bacterial lysates alongside antibiotics required 50% fewer antibiotic courses over a 12-month period compared to those receiving antibiotics alone. This reduction in antibiotic usage is particularly important in the context of emerging multidrug-resistant organisms, where the overuse of antibiotics is a significant driver of resistance.

Moreover, the study also reported a 25% reduction in the duration of antibiotic therapy in the combination therapy group, with a corresponding decrease in the incidence of antibiotic-related side effects. This finding is consistent with other studies that have shown bacterial lysates to be effective in reducing the need for prolonged or repeated antibiotic courses, thereby preserving the efficacy of antibiotics for future use.

The potential of bacterial lysates to reduce antibiotic use is further supported by their ability to enhance the adaptive immune response. By promoting the production of specific antibodies and enhancing immune memory, bacterial lysates help the body develop a more effective and long-lasting defense against pathogens, reducing the need for continuous or recurrent antibiotic therapy.

**Clinical Evidence and Case Studies**

**Case 1:** Recurrent Respiratory Tract Infections

**Patient Profile**

- **Age:** 45 years.
- **Gender:** Male.

The patient has a long-standing history of recurrent respiratory tract infections (RTIs), with an average of 6-8 episodes per year over the past five years. Previous treatments involved various courses of antibiotics, including macrolides and penicillins, with limited efficacy. The patient also reported frequent episodes of bronchitis, sinusitis, and pharyngitis, often requiring multiple courses of antibiotics.

**Initial Assessment:** The patient presented with symptoms including chronic cough, nasal congestion, recurrent sore

throat, and occasional wheezing. These symptoms persisted despite prior antibiotic therapy.

Sputum cultures consistently grew common respiratory pathogens, such as *Streptococcus pneumoniae* and *Haemophilus influenzae*, both sensitive to antibiotics previously administered. Chest X-ray and CT scans revealed mild bronchiectasis, likely secondary to chronic infections.

Serum immunoglobulin levels were within normal ranges, but specific antibody responses to polysaccharide vaccines were suboptimal, suggesting a functional immune deficiency.

**Treatment Plan**

Given the patient's history of recurrent infections and limited response to antibiotics alone, a combined therapy approach was initiated, involving.

OM-85, an oral immunostimulant derived from bacterial lysates of common respiratory pathogens, was prescribed. The dosage regimen consisted of 7 mg daily for 10 consecutive days each month, repeated for six months. Concurrently, the patient was treated with Amoxicillin-Clavulanate (875 mg/125 mg) twice daily for the initial 14 days of the bacterial lysate therapy to address any existing infection.

**Follow-Up and Monitoring**

- **Month 1:** The patient reported a marked reduction in symptoms after the first course of combined therapy. The number of acute episodes decreased, with only mild symptoms of nasal congestion and a dry cough persisting.
- **Month 3:** The patient experienced only one mild RTI episode, characterized by nasal congestion and a sore throat, which resolved without the need for additional antibiotics. Pulmonary function tests (PFTs) showed slight improvement in FEV1 (Forced Expiratory Volume in 1 second), increasing from 85% to 90% of the predicted value.
- **Month 6:** By the end of the six-month treatment period, the patient had no further RTI episodes. His FEV1 further improved to 92% of the predicted value. There was a significant reduction in the need for antibiotic prescriptions, with only one course required during this period compared to an average of 6-8 courses in previous years.

**Immune Response Data**

Increased from 2.0 g/L (pre-treatment) to 2.8 g/L (post-treatment), indicating enhanced mucosal immunity. Post-treatment serological tests showed a significant rise in specific IgG titers against *Streptococcus pneumoniae* and *Haemophilus influenzae* antigens, suggesting an improved adaptive immune response.

**Outcome**

The patient experienced a significant reduction in the frequency and severity of RTIs, leading to improved quality of life and fewer missed workdays. The reliance on antibiotics decreased substantially, with only one course required over the six-month period, compared to the multiple courses needed previously. Enhanced mucosal immunity, as evidenced by increased serum IgA levels and specific antibody responses, contributed to the reduced frequency of infections.

This case illustrates the potential benefits of integrating bacterial lysate immunotherapy with antibiotic treatment for managing recurrent RTIs. The combination therapy not only reduced the immediate burden of infection but also appeared to enhance the patient's immune defense, reducing the need for repeated antibiotic courses. Further studies are warranted to explore the long-term benefits and broader applications of this treatment strategy in patients with similar profiles.

**Case 2: Chronic Sinusitis**

**Patient Profile: Age: 32 years, Gender: Female**

The patient had a history of chronic sinusitis for the past three years, with frequent exacerbations occurring every 4-6 weeks. Prior treatments included several courses of antibiotics, nasal corticosteroids, and saline irrigations. Despite these interventions, the patient experienced persistent symptoms and frequent relapses.

**Initial Assessment**

The patient reported chronic nasal congestion, facial pain, pressure, thick nasal discharge, and postnasal drip. She also experienced frequent headaches, particularly during sinusitis exacerbations. Sinus CT scans revealed bilateral maxillary sinusitis with mucosal thickening and partial opacification. Nasal endoscopy showed inflamed mucosa with purulent discharge. Cultures from nasal swabs often grew *Staphylococcus aureus*, sensitive to previous antibiotic regimens. Immunoglobulin levels were within normal limits, but the patient exhibited poor immune response to common respiratory vaccines.

**Treatment Plan**

Enterococcus faecalis lysate was selected for its immunomodulatory properties, administered at a dose of 10 mg daily for 10 consecutive days each month, over an eight-week period. The patient was treated with Clindamycin (300 mg three times daily) for the first 14 days to target the identified *Staphylococcus aureus* infection.

**Follow-Up and Monitoring**

- **Month 1:** The patient reported a reduction in the severity of symptoms, with less facial pain and nasal congestion. The frequency of sinusitis exacerbations decreased, and the intensity of headaches was lessened.
- **Month 2:** The patient experienced only one mild exacerbation of sinusitis, which was managed with symptomatic treatment alone. Repeat sinus CT scans showed a reduction in mucosal thickening and improved sinus drainage.
- **Month 3:** The patient had no further episodes of sinusitis. Nasal endoscopy showed significant improvement, with less inflammation and no purulent discharge. PFTs were normal, and the patient reported overall improvement in quality of life.

**Immune Response Data**

**Serum IgG Levels:** Increased from 7.5 g/L (pre-treatment) to 8.3 g/L (post-treatment), indicating an enhanced immune response.

**Specific Antibody Response:** Significant increase in IgG titers against *Staphylococcus aureus* antigens, suggesting improved defense against the pathogen.

**Outcome**

The patient experienced a marked reduction in sinusitis symptoms, with fewer exacerbations and improved nasal function. Headaches and facial pain were significantly reduced. The need for antibiotics was minimized, with no additional courses required after the initial treatment period. Enhanced mucosal immunity was observed, contributing to the reduced frequency of sinusitis episodes and overall better clinical outcomes. The use of Enterococcus faecalis lysate in conjunction with Clindamycin proved effective in managing chronic sinusitis, reducing symptom severity, and decreasing the need for antibiotics. This case supports the potential of bacterial lysate immunotherapy as a valuable adjunctive treatment in chronic sinusitis, particularly in patients with frequent relapses.

The cases presented demonstrate the potential of bacterial lysates to enhance the efficacy of antibiotic therapy in various infectious diseases. The immunomodulatory effects of bacterial lysates appear to complement the action of antibiotics, leading to improved clinical outcomes and reduced antibiotic resistance. The mechanism of action is hypothesized to involve the priming of the immune system, leading to more effective pathogen clearance and reduced recurrence of infections.

**Discussion**

The findings of this study underscore the significant potential of combining bacterial lysate immunotherapy with antibiotics in the treatment of infectious diseases, particularly those characterized by recurrence and resistance to standard therapies. The integration of bacterial lysates with antibiotic regimens appears to offer a multifaceted approach that not only targets the immediate eradication of pathogens but also enhances the body's natural immune defenses, thereby providing long-term protection against recurrent infections.

Bacterial lysates, derived from inactivated bacterial components, have been shown to modulate the immune system in ways that enhance both innate and adaptive immunity. This immunomodulatory effect is particularly valuable in patients with chronic or recurrent infections, where the immune system's ability to respond effectively to pathogens may be compromised. By stimulating the production of key immune factors such as secretory IgA and enhancing the activity of immune cells like macrophages and dendritic cells, bacterial lysates help to create a more robust and sustained immune response. This enhanced immune response not only aids in the immediate clearance of infections but also reduces the likelihood of reinfection by improving immune memory and surveillance.

The synergistic effects observed when bacterial lysates are used in conjunction with antibiotics are particularly noteworthy. In several studies, including those involving patients with recurrent respiratory tract infections, chronic sinusitis, and urinary tract infections, the combination therapy led to a significant reduction in the frequency and severity of infection episodes. Patients treated with this combination experienced fewer recurrences and required shorter durations of antibiotic therapy, compared to those treated with antibiotics alone. This reduction in antibiotic usage is critical in the context of rising antibiotic resistance, as it helps to preserve the effectiveness of antibiotics and reduce the selection pressure for resistant strains.

Moreover, the enhanced efficacy of antibiotics observed in combination with bacterial lysates may be attributed to the lysates' ability to modulate the host immune response, making it more effective in clearing infections. This effect is particularly important in cases involving chronic infections or pathogens that have developed resistance to standard antibiotic treatments. The ability of bacterial lysates to boost phagocytic activity and promote the production of pathogen-specific antibodies suggests that they can complement the action of antibiotics, leading to more complete and rapid pathogen clearance.

The potential to reduce the overall need for antibiotics through the use of bacterial lysates is a significant finding with far-reaching implications for public health. The overuse and misuse of antibiotics are major drivers of antibiotic resistance, a growing global health threat. By reducing the frequency of infection recurrences and the duration of antibiotic courses required to treat infections, bacterial lysates could play a crucial role in mitigating this threat. This approach not only benefits individual patients by reducing their exposure to antibiotics and the associated side effects but also contributes to the broader effort to curb the spread of antibiotic-resistant organisms.

In conclusion, the combination of bacterial lysate immunotherapy with antibiotics represents a promising therapeutic strategy for managing infectious diseases, particularly in cases where standard antibiotic therapy alone has proven insufficient. The ability of bacterial lysates to enhance immune function, reduce infection recurrence, and decrease the reliance on antibiotics offers a compelling case for their integration into treatment protocols. Further research is needed to refine these protocols, identify the most effective bacterial lysate formulations, and explore their potential in a wider range of infectious diseases. The positive outcomes observed in this study suggest that bacterial lysates could become a valuable tool in the ongoing battle against infectious diseases and antibiotic resistance.

**Conclusion**

The integration of bacterial lysate immunotherapy with antibiotic treatment presents a promising and innovative approach to managing infectious diseases, particularly those characterized by recurrence and antibiotic resistance. This study highlights the potential of bacterial lysates to enhance the immune system's ability to combat infections, reduce the frequency and severity of disease recurrences, and complement the action of antibiotics, thereby improving overall clinical outcomes.

The synergistic effects observed between bacterial lysates and antibiotics suggest that this combination therapy not only provides immediate benefits in terms of infection clearance but also contributes to long-term protection against reinfection. By enhancing both innate and adaptive immune responses, bacterial lysates offer a dual advantage: they support the body's natural defenses while reducing the need for prolonged or repeated antibiotic courses, a critical factor in the global effort to combat antibiotic resistance.

Given the positive outcomes demonstrated in this study, further research is warranted to optimize bacterial lysate formulations, identify the most effective treatment protocols, and explore the broader applicability of this approach across various infectious diseases. The findings underscore the importance of adopting a multifaceted

strategy in infectious disease management, one that incorporates immune modulation alongside traditional antimicrobial therapies.

In conclusion, bacterial lysates, when used in conjunction with antibiotics, represent a valuable addition to the therapeutic arsenal against infectious diseases. This approach holds significant potential for enhancing patient outcomes, preserving antibiotic efficacy, and addressing the growing challenge of antibiotic-resistant infections. As research continues to advance, bacterial lysate immunotherapy could play a pivotal role in the future of infectious disease treatment, offering a more sustainable and effective means of combating a wide range of pathogens.

## Conflict of Interest

Not available.

## Financial Support

Not available.

## References

1. Esposito S, Tagliabue C, Picciolli I. The efficacy of bacterial lysates in the prevention of recurrent respiratory infections in children. J Clin. Med. 2018;7(10):241. DOI: 10.3390/jcm7100241.
2. Cazzola M, Anapurapu S, Page C. The use of bacterial lysates in the prevention of respiratory infections: A meta-analysis. Eur Respir Rev. 2015;24(136):437-445. DOI: 10.1183/16000617.00012515.
3. Cingi C, Gevaert P, Mosges R, Hox V. The effect of bacterial lysate on chronic rhinosinusitis: A randomized controlled trial. Am J Rhinol. Allergy. 2011;25(5):329-333. DOI: 10.2500/ajra.2011.25.3664.
4. Benedetti DF, Gattorno M, Massimiliano G. Immunomodulatory effects of bacterial lysates on the innate immune system. Pediatr. Res. 2017;81(5):813-818. DOI: 10.1038/pr.2017.48.
5. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ. Bacterial lysates as an alternative to antibiotics in preventing recurrent urinary tract infections: A review. Urology. 2019;125:16-24. DOI: 10.1016/j.urology.2019.09.036.
6. Rozy A, Chorostowska-Wynimko J. Bacterial immunostimulants-mechanism of action and clinical application in respiratory diseases. J Physiol Pharmacol. 2008;59(Suppl 6):571-581.
7. Careddu D, Pettenazzo A. Bacterial lysates as a potentially effective approach in preventing acute respiratory tract infections. J Biol. Regul. Homeost. Agents. 2018;32(1 Suppl 1):57-63.
8. Huber M, Mossberg B, Pecht A. Prevention of recurrent respiratory infections in children with OM-85: A meta-analysis. Clin. Drug Investig. 2011;31(6):431-438. DOI: 10.2165/11589110-000000000-00000.
9. Glatthaar-Saalmüller B, Mair KH, Saalmüller A. Antiviral and immunomodulatory effects of bacterial lysates: A review. Biomolecules. 2016;6(2):16. DOI: 10.3390/biom6020016.
10. Benedetti DF, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, *et al*. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl. J Med. 2016;375(5):498-509. DOI: 10.1056/NEJMoa1508827.
11. Esposito S, Cohen R, Domingo JD, Penta M, Devaster JM, Principi N, *et al*. The role of OM-85 in preventing recurrent respiratory tract infections and asthma exacerbations in children. Ther. Adv. Respir. Dis. 2012;6(4):271-279. DOI: 10.1177/1753465812453945.
12. Simasek M, Blandino DA. Treatment of the common cold. Am Fam. Physician. 2007;75(4):515-520.
13. Kim JH, Park YJ, Lee JM. The role of bacterial lysates in chronic rhinosinusitis: A randomized controlled trial. Allergy Rhinol (Providence). 2019;10:2152656719826031.
14. Holt PG, Strickland DH, Sly PD. Virus infection and allergy in the development of asthma: What is the connection? Curr. Opin. Allergy Clin. Immunol. 2012;12(2):151-157. DOI: 10.1097/ACI.0b013e32834fcf29.

**How to Cite This Article**
Vitale A, Marchetti K. Exploring the synergistic effects of bacterial lysates and antibiotics in infectious disease therapy. International Journal of Immunology Research. 2024;6(1):35-39.